Register Free
Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase I Oncology
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
What is being tested: The safety and efficacy of T cell engaging bi/tri-specific antibodies administered intravenously or subcutaneously, either as monotherapy or in combination…
21 Jul 2026 NCT06892522
● Recruiting Phase I Oncology
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
Drug Being Tested: GSK5533524, a novel investigational agent, is being evaluated in a first-in-human study as monotherapy and in combination regimens to establish safety,…
21 Jul 2026 NCT07438782
● Recruiting Phase I Oncology
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Drug and mechanism: LOXO-783 is being tested as a targeted therapy for breast cancer and solid tumors with specific genetic mutations, representing a precision…
20 Jul 2026 NCT05307705
active not recruiting Phase I
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants
A safety and dose study of new drug UCB5285 in healthy people, including Japanese volunteers.
17 Jul 2026 NCT07286682
● Recruiting Phase I Gastroenterology
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
A new gene-editing treatment (VERVE-201) was tested in patients with severe high cholesterol to assess safety and whether it reduces cholesterol levels.
17 Jul 2026 NCT06451770
● Recruiting Phase I Respiratory / COPD / Asthma
Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants
What is being tested: A controlled human infection model (CHIM) administering SARS-CoV-2 Omicron EG.5.1 variant via intranasal drops to evaluate breakthrough infections and immune…
17 Jul 2026 NCT07397455
active not recruiting Phase I / Phase II
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
Single-dose gene therapy injection for wet age-related macular degeneration, with safety and vision outcomes tracked over five years.
16 Jul 2026 NCT06660667
active not recruiting Phase I
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
Phase 1 trial testing a new drug (GSK4771261) in healthy people and those with polycystic kidney disease to assess safety and effectiveness.
15 Jul 2026 NCT06734234
active not recruiting Phase I / Phase II Oncology
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Early-stage trial testing JNJ-63723283 (anti-PD-1 antibody) to find safe doses and effectiveness across multiple advanced cancers.
14 Jul 2026 NCT02908906
● Recruiting Phase I Oncology
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
What is being tested: mRNA-4359, a novel immunotherapy agent, is being evaluated for safety and tolerability when administered as monotherapy and in combination with…
14 Jul 2026 NCT05533697
● Recruiting Phase I Oncology
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
What is being tested: GSK5764227, a novel therapeutic agent, is being evaluated for safety, efficacy, and pharmacokinetics as monotherapy or in combination with other…
14 Jul 2026 NCT06885034
● Recruiting Phase I / Phase II Rare Diseases
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
LY3884961 (PR001) safety and tolerability study in adults with peripheral Gaucher disease across multiple dose levels over five years.
13 Jul 2026 NCT05487599
● Recruiting Phase I Oncology
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors
What is being tested: LRK-4189, an investigational agent, is being evaluated as a monotherapy and in combination regimens for treating solid tumors, with particular…
13 Jul 2026 NCT07498725
● Recruiting Phase I Oncology
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
LY4152199 is a novel investigational agent being evaluated for dose-optimisation, safety, and efficacy in patients with relapsed or refractory B-cell malignancies who have failed…
10 Jul 2026 NCT07101328
● Recruiting Phase I Oncology
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
What is being tested: ORIC-944, a novel therapeutic agent, is being evaluated both as monotherapy and in combination with androgen receptor pathway inhibitors (ARPIs)…
09 Jul 2026 NCT05413421
● Recruiting Phase I Oncology
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
NXP900 is a first-in-human investigational agent being tested in a dose escalation and expansion study to determine safety, tolerability, and optimal dosing in patients…
09 Jul 2026 NCT05873686
● Recruiting Phase I / Phase II
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Gene therapy trial testing whether a single injection can enable the body to produce its own clotting factor in severe haemophilia B patients.
08 Jul 2026 NCT06379789
active not recruiting Phase I Neurology
A Study to Assess THN391 in Subjects With Alzheimer’s Disease
Early-stage trial testing whether THN391 drug is safe and tolerable in Alzheimer's disease patients compared to placebo.
08 Jul 2026 NCT06814730
active not recruiting Phase I / Phase II
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
Testing whether combining vorasidenib with standard chemotherapy is safe and effective for IDH-mutant brain tumours.
08 Jul 2026 NCT06478212
● Recruiting Phase I Oncology
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
What is being tested: Ponatinib, a tyrosine kinase inhibitor, is being evaluated for safety, tolerability, pharmacokinetics, and efficacy in paediatric patients aged 1-18 years…
08 Jul 2026 NCT03934372
active not recruiting Phase I / Phase II
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
New dual-targeted CAR-T cell therapy tested in relapsed/refractory B-cell lymphoma and high-risk newly diagnosed DLBCL.
06 Jul 2026 NCT05421663
active not recruiting Phase I Oncology
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
Trial testing new cancer drug amivantamab alone and combined with existing treatments in advanced lung cancer patients to find safe, effective doses.
06 Jul 2026 NCT02609776
active not recruiting Phase I Oncology
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
This study tested whether a new prostate cancer drug (ARN-509) can be safely combined with abiraterone acetate, and whether dose adjustments are needed.
06 Jul 2026 NCT02123758
active not recruiting Phase I Oncology
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Trial testing whether teclistamab combined with other cancer drugs is safe and effective for multiple myeloma patients.
06 Jul 2026 NCT04722146
active not recruiting Phase I / Phase II Oncology
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
Testing two new drug combinations with glofitamab in patients with relapsed/refractory B-cell lymphoma to find safe doses and assess effectiveness.
06 Jul 2026 NCT03533283
active not recruiting Phase I / Phase II Gastroenterology
Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients
QEL-001 Trial Summary A study testing a personalised cell therapy to help liver transplant patients accept their donor organ without long-term immunosuppression.
02 Jul 2026 NCT05234190
● Recruiting Phase I Respiratory / COPD / Asthma
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer’s Disease
Drug Being Tested: DNL628 is a novel therapeutic agent undergoing Phase 1b evaluation for safety, tolerability, pharmacokinetics and pharmacodynamics in early Alzheimer's disease using…
01 Jul 2026 NCT07328451
● Recruiting Phase I Neurology
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
CC-97540, a novel oral immunomodulatory agent, is being evaluated for safety, tolerability, efficacy and pharmacokinetics across three distinct autoimmune neurological conditions: relapsing and progressive…
01 Jul 2026 NCT06220201
● Recruiting Phase I Oncology
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Drug being tested: Sacituzumab tirumotecan (MK-2870), a targeted antibody-drug conjugate, is being evaluated as monotherapy or in combination with other treatments for advanced or…
01 Jul 2026 NCT06428409
active not recruiting Phase I Oncology
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
New drug SNDX-5613 combined with chemotherapy tested for safety and effectiveness in newly diagnosed acute myeloid leukaemia.
30 Jun 2026 NCT06226571
● Recruiting Phase I / Phase II Rheumatology
Controlling Hyperactive Immunity With Long-lived Lymphocytes
Early-stage trial testing genetically-modified immune cells to treat severe autoimmune diseases (systemic sclerosis and rheumatoid arthritis).
30 Jun 2026 NCT07473154
● Recruiting Phase I
PS-002 for the Treatment of IgA Nephropathy in Adults
PS-002 is a novel therapeutic agent being tested in a first-in-human trial to evaluate its safety, tolerability, and preliminary effectiveness in treating primary IgA…
30 Jun 2026 NCT07182227
● Recruiting Phase I Oncology
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
What is being tested: Multiple anti-cancer agents are being evaluated for safety, tolerability, pharmacokinetics, and preliminary efficacy in a platform study design, allowing simultaneous…
30 Jun 2026 NCT07590934
● Recruiting Phase I Oncology
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
What is being tested: CryptiVax-1001, an immunotherapeutic vaccine, is being evaluated as a maintenance treatment in patients with advanced high-grade serous ovarian, fallopian tube,…
29 Jun 2026 NCT07665515
active not recruiting Phase I / Phase II Oncology
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Trial testing pembrolizumab combined with various drugs to treat advanced prostate cancer resistant to hormone therapy.
26 Jun 2026 NCT02861573
active not recruiting Phase I
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial comparing two manufacturing methods of teclistamab to ensure the new process produces equivalent drug with same effectiveness in multiple myeloma.
26 Jun 2026 NCT06425991
active not recruiting Phase I Respiratory / COPD / Asthma
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
Two new mRNA vaccines against RSV and related respiratory viruses are being tested for safety and effectiveness in infants aged 5-24 months.
26 Jun 2026 NCT05743881
● Recruiting Phase I Oncology
Study of HLD-0915 in Patients With Metastatic Prostate Cancer
Drug and indication: HLD-0915 is being tested for safety and efficacy in metastatic prostate cancer patients who have failed previous systemic treatments, with planned…
26 Jun 2026 NCT06800313
● Recruiting Phase I Oncology
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PC14586 (rezatapopt) is being evaluated as a monotherapy in patients with advanced solid tumors carrying the TP53 Y220C mutation, targeting restoration of mutant p53…
26 Jun 2026 NCT04585750
● Recruiting Phase I Oncology
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Treatment being tested: YTB323, a novel CAR-T cell therapy designed to target and eliminate autoreactive B cells in treatment-resistant generalized myasthenia gravis (gMG), representing…
26 Jun 2026 NCT06704269
active not recruiting Phase I / Phase II Oncology
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Early-stage trial testing vimseltinib drug in patients with advanced cancers and tenosynovial giant cell tumours to find safe doses and effectiveness.
25 Jun 2026 NCT03069469
active not recruiting Phase I Oncology
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
New cancer drug GSK4381562 tested for first time in humans with advanced tumours to check safety and how the body processes it.
25 Jun 2026 NCT05277051
● Recruiting Phase I Neurology
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
Being tested: Safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of a new subcutaneous formulation of ocrelizumab (an anti-CD20 monoclonal antibody) in multiple sclerosis patients, with…
25 Jun 2026 NCT07667322
● Recruiting Phase I Respiratory / COPD / Asthma
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
What is being tested: The study compares the effectiveness and potency of salbutamol (albuterol) delivered via metered dose inhalers using two different propellant systems—HFA-152a…
24 Jun 2026 NCT06433921
● Recruiting Phase I Oncology
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Drug being tested: CCS1477 (inobrodib), a novel therapeutic agent being evaluated for safety, tolerability, pharmacokinetics and biological activity in a Phase 1/2a trial across…
24 Jun 2026 NCT04068597
active not recruiting Phase I / Phase II Oncology
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Entrectinib tested in children with advanced solid or brain tumours carrying specific gene fusions to find safe doses and effectiveness.
23 Jun 2026 NCT02650401
● Recruiting Phase I Oncology
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
MK-1045 is being evaluated as a potential treatment for two distinct subtypes of non-Hodgkin lymphoma: follicular lymphoma (indolent/slow-growing) and diffuse large B-cell lymphoma (aggressive/fast-growing),…
23 Jun 2026 NCT07519772
● Recruiting Phase I / Phase II Rare Diseases
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
Single intravenous gene therapy infusion (SGT-003) tested for safety and effectiveness in children with Duchenne muscular dystrophy across age groups.
22 Jun 2026 NCT06138639
● Recruiting Phase I Oncology
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
What is being tested: EP0062, a novel therapeutic agent, is being evaluated as a single agent and in combination with standard-of-care treatments to determine…
22 Jun 2026 NCT05573126
● Recruiting Phase I Oncology
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Treatment being tested: Tulmimetostat (DZR123/CPI-0209), a novel investigational agent evaluated as monotherapy and combined with enzalutamide, in a first-in-human trial assessing safety, tolerability, pharmacokinetics,…
22 Jun 2026 NCT04104776